Anbio Biotechnology (NASDAQ:NNNN) Shares Shorted: Short Interest Down 42.4% in October

Anbio Biotechnology (NASDAQ:NNNN) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 31,124 shares, a decline of 42.4% from the September 30th total of 54,022 shares. Based on an average trading volume of 46,624 shares, the short-interest ratio is currently 0.7 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Anbio Biotechnology Trading Up 4.6%

Shares of NNNN stock traded up $0.15 on Tuesday, hitting $3.52. The company’s stock had a trading volume of 4,637 shares, compared to its average volume of 77,166. The stock’s 50 day moving average is $5.40 and its 200-day moving average is $16.66. Anbio Biotechnology has a fifty-two week low of $3.09 and a fifty-two week high of $44.73.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.